Difference between revisions of "Part:BBa K404114"
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
<partinfo>BBa_K404114 short</partinfo> | <partinfo>BBa_K404114 short</partinfo> | ||
+ | <br /> | ||
+ | {| style="color:black" cellpadding="6" cellspacing="1" border="2" align="right" | ||
+ | ! colspan="2" style="background:#66bbff;"|[https://parts.igem.org/Part:BBa_K404114 [AAV2]-left-ITR_pCMV] | ||
+ | |- | ||
+ | ! colspan="2"|[[Image:Freiburg10_Vectorplasmid precursors 1.png|200px]] | ||
+ | |- | ||
+ | |'''BioBrick Nr.''' | ||
+ | |[https://parts.igem.org/Part:BBa_K404114 BBa_K404114] | ||
+ | |- | ||
+ | |'''RFC standard''' | ||
+ | |[https://parts.igem.org/Help:Assembly_standard_10 RFC 10] | ||
+ | |- | ||
+ | |'''Requirement''' | ||
+ | |pSB1C3<br> | ||
+ | |- | ||
+ | |'''Source''' | ||
+ | |pAAV_MCS provided by Stratagene | ||
+ | |- | ||
+ | |'''Submitted by''' | ||
+ | |[http://2010.igem.org/Team:Freiburg_Bioware FreiGEM 2010] | ||
+ | |} | ||
+ | <br /> | ||
− | [[Image:Freiburg10_Vectorplasmid precursors 1.png| | + | [[Image:Freiburg10_Vectorplasmid precursors 1.png|left|thumb|480px]]<br /><br /><br /><br /><br /><br /><br /><br /><br /><br /><br /><br /><br /><br /><br /> |
<html> | <html> | ||
<head> | <head> |
Revision as of 15:26, 27 October 2010
[AAV2]-left-ITR_pCMV
[AAV2-left-ITR_pCMV] | |
---|---|
BioBrick Nr. | BBa_K404114 |
RFC standard | RFC 10 |
Requirement | pSB1C3 |
Source | pAAV_MCS provided by Stratagene |
Submitted by | [http://2010.igem.org/Team:Freiburg_Bioware FreiGEM 2010] |
Producing
recombinant virus particles for therapeutical applications is, besides
specific
cell targeting, purification and quantification assays of AAV-2, one
intention
of the Virus Construction Kit provided by the iGEM team
Freiburg_Bioware 2010.
For obtaining a modular toolkit, the complex biological system of the
Adeno-associated virus serotype 2 was examined by an exhaustive
literature
search. Subsequently, the essential components for AAV-2 particle
production
were extracted and redesigned to match the iGEM standard.
The provided tripartite system is independent of a superinfection of Adeno- or herpes simplex viruses since the genes encoding the required helper-proteins are co-transfected. Inside the eukaryotic host cell, the DNA sequence containing the inverted terminal repeats (ITRs) is extracted and later encapsidated into the preformed capsids after production of single-stranded DNA. Consequently, this plasmid is known as the vector plasmid (pGOI). Promoter, beta-globin intron and the hGH terminator signal are flanked by the ITRs (ITRs, BBa_K404100 and BBa_K404101) and regulate transgene expression. The vector plasmid containing the desired gene of interest is cotransfected with the RepCap plasmid (BBa_K404001, BBa_K404002 or BBa_K404003) and the pHelper plasmid. To obtain the fully assembled vector plasmid, several assembly steps have to be performed.
Facilitating the cloning steps, the iGEM team Freiburg_Bioware 2010 provides the 5´nucleotide components in respect to the desired gene of interest, consisting of the left inverted terminal repeat (BBa_K404100) followed by the CMV promoter (BBa_K404102).
Sequence and Features
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25COMPATIBLE WITH RFC[25]
- 1000COMPATIBLE WITH RFC[1000]